Skip to main content

Table 3 Cox proportional-hazards regression: univariate and multivariate analyses of Progression Free Survival

From: A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

  Progression Free Survival
Univariate Analysis Multivariate Analysis
VARIABLE (Comparator) HR (95% CI); p - value HR (95% CI); p - value
BMI
≥ 25 vs < 25
0.46 (0.39–0.54); p < 0.0001 0.71 (0.56–0.90); p < 0.0001
Weighta 0.97 (0.96–0.98); p < 0.0001 0.99 (0.98–1.01); p = 0.1580
irAEs of any grade
Yes vs No
0.48 (0.41–0.57); p < 0.0001 0.67 (0.54–0.83); p = 0.0002
Primary Tumor (NSCLC)
 Melanoma 0.52 (0.42–0.66); p < 0.0001 0.67 (0.53–0.85); p = 0.0008
 Kidney 0.72 (0.58–0.91); p = 0.0062 0.67 (0.53–0.84); p = 0.0008
 Others 1.08 (0.65–1.78); p = 0.7556 0.69 (0.41–1.15); p = 0.1533
Sex
 Male vs
 Female
1.20 (1.01–1.42); p = 0.0314 1.03 (0.86–1.22); p = 0.7252
Age
 Elderly vs
 Non-elderly
0.96 (0.82–1.12); p = 0.6394
Treatment line
 Non-first vs First
1.62 (1.33–1.96); p < 0.0001 1.61 (1.32–1.93); p < 0.0001
N° of metastatic sites
 > 2 vs ≤ 2
1.46 (1.27–1.68); p < 0.0001 1.42 (1.21–1.67); p < 0.0001
ECOG PS
 ≥2 vs 0–1
2.60 (2.13–3.17); p < 0.0001 2.06 (1.67–2.52); p < 0.0001
  1. aWeight was used as a continuous variable